Why David Davidson Unloaded 3,000 Shares of bluebird bio, Inc. (BLUE)?; South Jersey Industries (SJI) Has 1.45 Sentiment

bluebird bio, Inc. (NASDAQ:BLUE) Logo

Sentiment for South Jersey Industries Inc (SJI)

South Jersey Industries Inc (SJI) investors sentiment increased to 1.45 in 2017 Q4. It’s up 0.21, from 1.24 in 2017Q3. The ratio improved, as 97 funds increased and opened new holdings, while 67 reduced and sold stock positions in South Jersey Industries Inc. The funds in our database now possess: 55.25 million shares, up from 54.81 million shares in 2017Q3. Also, the number of funds holding South Jersey Industries Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 15 Reduced: 52 Increased: 68 New Position: 29.

The stock increased 2.28% or $0.68 during the last trading session, reaching $30.51. About 463,260 shares traded. South Jersey Industries, Inc. (SJI) has declined 22.60% since April 16, 2017 and is downtrending. It has underperformed by 34.15% the S&P500.

Analysts await South Jersey Industries, Inc. (NYSE:SJI) to report earnings on May, 8. They expect $0.91 EPS, up 26.39% or $0.19 from last year’s $0.72 per share. SJI’s profit will be $72.24M for 8.38 P/E if the $0.91 EPS becomes a reality. After $0.50 actual EPS reported by South Jersey Industries, Inc. for the previous quarter, Wall Street now forecasts 82.00% EPS growth.

South Jersey Industries, Inc., through its subsidiaries, provides energy-related services and products. The company has market cap of $2.42 billion. The firm engages in the purchase, transmission, and sale of natural gas. It currently has negative earnings. It also sells natural gas and pipeline transportation capacity on a wholesale basis to residential, commercial, and industrial clients on the interstate pipeline system, as well as transports natural gas, which is purchased directly from producers or suppliers to their customers.

Ratings analysis reveals 0 of South Jersey Industries’s analysts are positive. Out of 3 Wall Street analysts rating South Jersey Industries, 0 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. SJI was included in 3 notes of analysts from September 8, 2016. The rating was downgraded by Guggenheim to “Neutral” on Monday, January 9. The rating was initiated by Morgan Stanley on Thursday, September 8 with “Equal-Weight”. The rating was downgraded by Williams Capital Group to “Hold” on Wednesday, November 23.

Roffman Miller Associates Inc Pa holds 2.1% of its portfolio in South Jersey Industries, Inc. for 543,916 shares. Crow Point Partners Llc owns 325,400 shares or 1.6% of their US portfolio. Moreover, Cutter & Co Brokerage Inc. has 0.98% invested in the company for 76,010 shares. The Illinois-based Vaughan David Investments Inc Il has invested 0.79% in the stock. Clear Harbor Asset Management Llc, a New York-based fund reported 120,551 shares.

The stock decreased 1.65% or $2.85 during the last trading session, reaching $170.2. About 348,012 shares traded. bluebird bio, Inc. (NASDAQ:BLUE) has risen 86.28% since April 17, 2017 and is uptrending. It has outperformed by 74.73% the S&P500.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $8.51 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

Among 26 analysts covering bluebird bio (NASDAQ:BLUE), 14 have Buy rating, 2 Sell and 10 Hold. Therefore 54% are positive. bluebird bio has $309.0 highest and $14 lowest target. $184.96’s average target is 8.67% above currents $170.2 stock price. bluebird bio had 92 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, December 11 by SunTrust. As per Monday, December 11, the company rating was maintained by Cantor Fitzgerald. The company was initiated on Tuesday, October 20 by Oppenheimer. Leerink Swann maintained bluebird bio, Inc. (NASDAQ:BLUE) rating on Wednesday, November 1. Leerink Swann has “Buy” rating and $162.0 target. Wells Fargo initiated bluebird bio, Inc. (NASDAQ:BLUE) on Friday, December 4 with “Outperform” rating. The stock of bluebird bio, Inc. (NASDAQ:BLUE) has “Buy” rating given on Friday, March 16 by William Blair. The rating was maintained by Morgan Stanley on Monday, February 26 with “Equal-Weight”. Morgan Stanley maintained bluebird bio, Inc. (NASDAQ:BLUE) on Wednesday, June 14 with “Hold” rating. The stock of bluebird bio, Inc. (NASDAQ:BLUE) earned “Buy” rating by Cowen & Co on Friday, June 23. The company was maintained on Wednesday, February 21 by Cantor Fitzgerald.

David Davidson, an insider of Bluebird Bio Inc, currently Chief Medical Officer recently disclosed a sizable transaction with the SEC. As exposed in the public report, David Davidson purchased 3,000 shares of the Massachusetts-based Bluebird Bio Inc, priced at $180.2 per share. $540,508 USD was the transaction’s value. The SEC filing’s date was April 16, 2018. It seems he is very active lately as in the last 30 days, he sold additional 22,000 shares of the company, worth $3,685,387 USD. The regulatory filing shows that David Davidson now holds roughly 0.05% of the Massachusetts-based company’s total market cap (Market Capitalization is a measurement of business value based on share price and number of shares outstanding)

Investors sentiment decreased to 1.51 in Q4 2017. Its down 0.28, from 1.79 in 2017Q3. It worsened, as 21 investors sold bluebird bio, Inc. shares while 79 reduced holdings. 71 funds opened positions while 80 raised stakes. 50.71 million shares or 3.40% more from 49.05 million shares in 2017Q3 were reported. Raymond James Fincl Svcs Advsrs Inc owns 3,117 shares. Fmr Ltd holds 7.36M shares or 0.15% of its portfolio. Cormorant Asset Mngmt Ltd Liability Co reported 1.49% stake. Us National Bank & Trust De has 31 shares for 0% of their portfolio. Bnp Paribas Arbitrage Sa holds 10,049 shares. Twin Tree Limited Partnership accumulated 1,210 shares. Millennium Mgmt holds 0% or 14,670 shares. Moreover, Mutual Of America Mngmt Ltd Limited Liability Company has 0.11% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 41,956 shares. Advisory Serv Network Limited Liability Company has 40 shares for 0% of their portfolio. Baillie Gifford & invested 1.15% in bluebird bio, Inc. (NASDAQ:BLUE). Crow Point Prns Lc reported 0.01% in bluebird bio, Inc. (NASDAQ:BLUE). New York-based Cornerstone Mngmt Holding Limited Liability Co has invested 0.02% in bluebird bio, Inc. (NASDAQ:BLUE). Columbus Circle invested 0.44% in bluebird bio, Inc. (NASDAQ:BLUE). Legal & General Grp Public Ltd Com has 0% invested in bluebird bio, Inc. (NASDAQ:BLUE). Peak6 Ltd Partnership has 0% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 1,555 shares.

Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on May, 2. They expect $-1.93 EPS, down 14.88% or $0.25 from last year’s $-1.68 per share. After $-2.52 actual EPS reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts -23.41% EPS growth.

Since October 20, 2017, it had 0 insider buys, and 21 selling transactions for $46.75 million activity. The insider Leschly Nick sold $942,298. Shares for $3.69M were sold by Davidson David. Shares for $530,530 were sold by Walsh Jeffrey T. on Friday, January 5. 25,000 shares were sold by Cole Jason, worth $4.90M. Shares for $3.38M were sold by HIGH SUSANNA GATTI. 7,000 shares were sold by Vachon Mark, worth $1.52 million. 2,250 bluebird bio, Inc. (NASDAQ:BLUE) shares with value of $406,550 were sold by Gregory Philip D.

South Jersey Industries, Inc. (NYSE:SJI) Institutional Positions Chart